-+ 0.00%
-+ 0.00%
-+ 0.00%

Virax Biolabs Presents Plans for 2027 U.S. Diagnostic Testing Launch

PUBT·11/18/2026 12:55:57
Listen to the news
Virax Biolabs Presents Plans for 2027 U.S. Diagnostic Testing Launch
  • Virax Biolabs targets a 2027 U.S. laboratory-developed test launch through a proposed hosted laboratory model, retaining assay ownership and testing revenue rights.
  • A potential FDA De Novo submission is targeted for 2028.
  • Results from the 160-participant UK study are delayed beyond the first quarter of 2027; analysis awaits assay finalization.
  • Cash totaled $5.12 million at September 30, 2026; targeted cumulative cost savings reach approximately $2.4 million through March 2028.
  • Exploratory pilot testing reported 88% specificity and 92% positive predictive value for post-acute infection syndromes.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Virax Biolabs Group Ltd. published the original content used to generate this news brief on November 18, 2026, and is solely responsible for the information contained therein.